Publications by authors named "Rohit V Goswamy"
Purpose: Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF) as a predictive biomarker of response is urgently needed.
Experimental Design: We present the first disclosure and preclinical development of a novel, selective ATR inhibitor, ART0380, and test its antitumor activity in multiple preclinical cancer models.
Article Synopsis
- Platelet transfusion refractoriness (PTR) due to HLA alloimmunization poses significant challenges in treating hematology-oncology patients, leading to higher risks of bleeding and mortality.
- A study involving 51 patients showed that the majority had hematological malignancies and were on chemotherapy, with notable incidences of clinically relevant bleeding and a bleeding-related mortality rate of 7.8%.
- There is a lack of standard management practices for PTR, with limited availability of HLA-matched products, highlighting the need for better testing and the potential benefits of future randomized trials on treatment options.
The value of event-free survival (EFS) as an end point in acute myeloid leukemia (AML) trials has been questioned. We hypothesized that rather than a surrogate for overall survival (OS), improvement in EFS may decrease the use of health care. In this retrospective study, we identified 400 patients with AML who were treated on first-line therapy trials and had OS between 2 and 36 months.
View Article and Find Full Text PDF